Weaning of inhaled nitric oxide: is there a best strategy?
Background: Inhaled nitric oxide (iNO) has been used in the treatment of pulmonary hypertension in neonates for many years. iNO was approved by the FDA in 1999 for hypoxic respiratory failure (HRF) in term and near term infants, defined as > 34 weeks gestational age (GA). iNO is used for persiste...
Main Authors: | Anita M. Ware, Sergio G. Golombek |
---|---|
Format: | Article |
Language: | English |
Published: |
Hygeia Press di Corridori Marinella
2015-04-01
|
Series: | Journal of Pediatric and Neonatal Individualized Medicine |
Subjects: | |
Online Access: | https://www.jpnim.com/index.php/jpnim/article/view/274 |
Similar Items
-
Inhaled nitric oxide as a rescue therapy in a preterm neonate with severe pulmonary hypertension: a case report
by: Martina Busè, et al.
Published: (2018-05-01) -
Beyond the inhaled nitric oxide in persistent pulmonary hypertension of the newborn
by: Mei-Yin Lai, et al.
Published: (2018-02-01) -
Nitric oxide synthase: non-canonical expression patterns
by: Mattila eJoshua, et al.
Published: (2014-10-01) -
Immune effector mechanisms of the nitric oxide pathway in malaria: cytotoxicity versus cytoprotection
by: Hossein Nahrevanian -
Modulating Nitric Oxide: Implications for Cytotoxicity and Cytoprotection
by: Igor Belenichev, et al.
Published: (2024-04-01)